Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Why highly expressed proteins evolve slowly
2005 StandoutNobel
Immune Rejection of Mouse Tumors Expressing Mutated Self
2009 StandoutNobel
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
2013 Science
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
2015 Science
Exploiting the Mutanome for Tumor Vaccination
2012
Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1
1996
High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo
1998
Hallmarks of Cancer: The Next Generation
2011 Standout
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma
2017
MHC Class I Antigens and Immune Surveillance in Transformed Cells
2007
Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity
1998
T cell defined tumor antigens
1997
Progress in human tumour immunology and immunotherapy
2001 Nature
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
2014
Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
2001
Inflammation and cancer
2002 StandoutNature
Strategies to overcome immune ignorance and tolerance
2002
Unrestricted cell cycling and cancer
1995
The shared tumor-specific antigen encoded by mouse geneP1A is a target not only for cytolytic T lymphocytes but also for tumor rejection
1998
A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis
1996
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Role of ERas in promoting tumour-like properties in mouse embryonic stem cells
2003 StandoutNatureNobel
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Reversal of human cellular senescence: roles of the p53 and p16 pathways
2003
Human cancer regression antigens
2013
Immunology and immunotherapy approaches for prostate cancer
2007
Tumor immunity and autoimmunity induced by immunization with homologous DNA.
1998
The Human T Cell Response to Melanoma Antigens
2006
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
1997 StandoutNobel
Human tumor antigens recognized by T-cells
1997
The Hallmarks of Cancer
2000 Standout
The cancer antigenome
2012
Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation
2010
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
2006
Immunity to Cancer Through Immune Recognition of Altered Self: Studies with Melanoma
2003
Cancer vaccines based on the identification of genes encoding cancer regression antigens
1997
Role of the retinoblastoma protein in the pathogenesis of human cancer.
1997 StandoutNobel
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
2014
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
2014
A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation
1999
Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma
2007
Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.
1994 StandoutNobel
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
1996
Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a
1997 Standout
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling
1998
Human tumor antigens for cancer vaccine development
1999
A Genome-Wide Transcriptional Analysis of the Mitotic Cell Cycle
1998
Unexpected Reduction of Skin Tumorigenesis on Expression of Cyclin-Dependent Kinase 6 in Mouse Epidermis
2011
cdk4 Deficiency Inhibits Skin Tumor Development but Does Not Affect Normal Keratinocyte Proliferation
2002
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation
1996 StandoutNobel
Oxidants, oxidative stress and the biology of ageing
2000 StandoutNature
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
1999 StandoutNobel
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
2016
Spinning molecular immunology into successful immunotherapy
2002
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
2014
Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse
1999 StandoutNobel
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
To cycle or not to cycle: a critical decision in cancer
2001
The Hallmarks of Aging
2013 Standout
Identification of human tumor antigens and its implications for diagnosis and treatment of cancer
2004
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
1996
Autoimmunity and tumor immunity induced by immune responses to mutations in self
2006
Immunogenic peptide discovery in cancer genomes
2015
Enhanced malignant tumorigenesis in Cdk4 transgenic mice
2003
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
2000
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
1996
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
1994
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
1994
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
1999 StandoutNobel
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70
2000 StandoutNobel
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
2014
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
1994
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
2014
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
1997
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Cancer Cell Cycles
1996 StandoutScience
HLA-Binding Properties of Tumor Neoepitopes in Humans
2014
The genome-wide expression response to telomerase deletion in Saccharomyces cerevisiae
2002 StandoutNobel
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
1994
The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68
1997
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
2006 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Human neoplasms elicit multiple specific immune responses in the autologous host.
1995
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
1998
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Invasive melanoma in Cdk4-targeted mice
2001
Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance
2002 StandoutNobel
Aerobic Copper-Catalyzed Organic Reactions
2013 Standout
Epitope Landscape in Breast and Colorectal Cancer
2008 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
1994
Cancer Genome Landscapes
2013 StandoutScience
Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes
1996
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning
2004
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
1995
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
1994
Neoantigens in cancer immunotherapy
2015 StandoutScience
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
1998
A unique tumor antigen produced by a single amino acid substitution
1995
Ectopic expression of dE2F and dDP induces cell proliferation and death in the Drosophila eye.
1996
Coupling and Uncoupling of Tumor Immunity and Autoimmunity
1999
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
Promotion of direct reprogramming by transformation-deficient Myc
2010 StandoutNobel
Personalized vaccines for cancer immunotherapy
2018 Science
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Serological analysis of human tumor antigens: molecular definition and implications
1997
Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma
1997
Point Mutation in Essential Genes with Loss or Mutation of the Second Allele
2001
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
2000
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Lack of Cyclin-Dependent Kinase 4 Inhibits c-myc Tumorigenic Activities in Epithelial Tissues
2004
Human tumor antigens recognized by T lymphocytes.
1996
Works of Catherine Wölfel being referenced
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
1993
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
2005
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
1995 Science